Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 4,660 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 4,660 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total value of $997,007.00. Following the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $1,546,644.55. This trade represents a 39.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Herriot Tabuteau also recently made the following trade(s):

• On Wednesday, August 5th, Herriot Tabuteau sold 45,004 shares of Axsome Therapeutics stock. The stock was sold at an average price of $212.01, for a total value of $9,541,298.04.
• On Wednesday, July 1st, Herriot Tabuteau sold 49,666 shares of Axsome Therapeutics stock. The shares were sold at an average price of $240.25, for a total value of $11,932,256.50.
• On Tuesday, June 9th, Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics stock. The stock was sold at an average price of $241.01, for a total transaction of $11,970,966.70.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $212.74 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The firm’s fifty day moving average price is $236.95 and its two-hundred day moving average price is $203.96. Axsome Therapeutics, Inc. has a 1 year low of $102.67 and a 1 year high of $260.19. The firm has a market capitalization of $10.95 billion, a P/E ratio of -57.03 and a beta of 0.65.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AXSM. Mizuho dropped their target price on shares of Axsome Therapeutics from $310.00 to $306.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. HC Wainwright reissued a “buy” rating and set a $290.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, July 15th. TD Cowen upped their price objective on Axsome Therapeutics from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price on shares of Axsome Therapeutics in a research note on Thursday, June 11th. Finally, Truist Financial raised Axsome Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $265.55.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Kemnay Advisory Services Inc. acquired a new stake in Axsome Therapeutics during the fourth quarter worth approximately $31,000. Hollencrest Capital Management grew its position in shares of Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after purchasing an additional 160 shares during the last quarter. Ameriflex Group Inc. bought a new position in shares of Axsome Therapeutics during the fourth quarter worth approximately $37,000. Advisory Services Network LLC bought a new position in shares of Axsome Therapeutics during the third quarter worth approximately $40,000. Finally, Farther Finance Advisors LLC lifted its holdings in Axsome Therapeutics by 602.6% during the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after purchasing an additional 235 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.